Key executives in Diamyd Medical intend to subscribe in full for their shares in the rights issue
Diamyd Medical is implementing a rights issue totaling approximately MSEK 68.8 before issue costs, and an over-allotment option of MSEK 20. Key executives in the Company intend to subscribe in full for their shares in the issue. Chairman of the Board Erik Nerpin also intends to subscribe for additional units without the support of preferential rights. The total amount for the units to which key executives intend to subscribe is SEK 384,667.Erik Nerpin’s current holding totals 20,533 series B shares. Nerpin intends to invest SEK 100,000 in the rights issue as follows: in addition to